CO-1686 hydrobromide,
1446700-26-0,
Rociletinib hydrobromide,
CV4XAQ7MUV,
UNII-CV4XAQ7MUV,
CO-1686 (hydrobromide),
CNX-419 hydrobroMide,
2-Propenamide, N-(3-((2-((4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)-4-pyrimidinyl)amino)phenyl)-, hydrobromide (1:1),
2-Propenamide, N-[3-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]-, hydrobromide (1:1),
CO 1686 hydrobromide,
BCP28816,
EX-A1584,
HY-15729A,
AKOS030526546,
CS-5247,
SB16489,
CO-1686 HBr salt,Rociletinib HBr salt; AVL-301 HBr salt, CNX-419 HBr salt,